High Insulin Levels: Definition, Pathophysiology and Long-Term Consequences

By Guillermo Salinas Araya · June 1, 2026 · Educational Material

In 1988, Gerald Reaven delivered the Banting Lecture at the American Diabetes Association, introducing the concept of Syndrome X — what we now know as insulin resistance. That lecture forever changed cardiology, endocrinology, and hepatology.

Medical Definition of High Insulin Levels

The term high insulin levels (hyperinsulinemia) refers to a clinical condition with established diagnostic criteria in recent medical literature. Understanding it requires distinguishing between the entity itself, its forms of presentation, and its underlying mechanisms. Updated international guidelines have reformulated several of these criteria over the last decade, expanding what conventional clinical practice has yet to incorporate.¹

Pathophysiology: How It Develops

The pathophysiological cascade of high insulin levels involves multiple parallel mechanisms that feed back into each other. The monocausal hypothesis has been replaced by integrative models that recognize the interaction of several axes:²

• Endocrine-metabolic axis: impaired insulin sensitivity and hepatic lipogenesis.
• Inflammatory axis: low-grade pro-inflammatory cytokines (TNF-α, IL-6, elevated high-sensitivity CRP).
• Mitochondrial axis: respiratory chain dysfunction and increased reactive oxygen species.
• Intestinal axis: altered microbiome, increased intestinal permeability, endotoxin translocation.
• Neuroendocrine axis: dysregulation of the hypothalamic-pituitary-adrenal axis with chronically elevated cortisol.

The simultaneous accumulation of these five impacts is what distinguishes the pathological state from the physiological state of compensatory tolerance. Patients may spend years with one or two active axes without clinical manifestation — until the convergence overwhelms adaptive mechanisms.

Clinical Signs and Symptoms

Clinical presentation is heterogeneous. In early phases, most patients are oligosymptomatic or asymptomatic.³ Signs and symptoms that guide diagnosis include:

• Unexplained fatigue, especially postprandial
• Progressive increase in waist circumference
• Skin changes (dark patches, skin tags, hair alterations)
• Sleep-wake cycle disturbances
• Neurocognitive symptoms: brain fog, difficulty concentrating, irritability
• Nonspecific laboratory findings: slightly elevated CRP, mild liver enzyme or lipid abnormalities often categorized as "high normal"
• Subtle ultrasound findings requiring targeted examination

Long-Term Consequences If Left Unaddressed

The natural history of high insulin levels without adequate intervention involves silent but predictable progression:⁴

• Increased cardiovascular risk independent of cholesterol levels
• Accelerated development of type 2 diabetes in patients with prediabetes
• Progression to structural organ damage within 5 to 15 years
• Increased cancer risk documented in longitudinal cohorts
• Progressive functional decline that reduces quality of life and healthy life expectancy

The therapeutic window of opportunity — the period during which the condition is completely reversible — is proportional to duration of exposure and the number of pathophysiological axes compromised. Each year lost without comprehensive intervention narrows that window.

Can It Be Reversed?

Contemporary clinical evidence is conclusive: in pre-irreversible stages, reversal is possible. But it requires addressing all five pathophysiological axes simultaneously, not sequentially or in isolation. This is where conventional approaches fail: they intervene on a single axis and leave the other four active.

The educational protocol we've designed — The Salinas Method — comprises 8 sequential phases. Each phase addresses a distinct mechanism in the cascade. Phases 1 and 2 prepare the cellular terrain and correct the microbiome. Phases 3 through 6 dismantle low-grade inflammation, mitochondrial dysfunction, insulin resistance, and cortisol axis disruption. Phases 7 and 8 consolidate the change and prevent relapse.

It's not a diet. It's not isolated fasting. It's not a supplement. It's a guided educational protocol, step by step, based on the most recent clinical evidence and designed so patients understand the rationale behind each action.

References

1. DeFronzo RA. Insulin resistance: a multifaceted syndrome. Diabetes Care. 1991. PubMed
2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988. PubMed
3. Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function. Diabetologia. 1985. PubMed
4. Petersen KF, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018. PubMed
5. Stumvoll M, et al. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005. PubMed
6. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways. Cell. 2012. PubMed

Educational material for informational purposes only. Does not replace medical consultation. Consult a licensed healthcare professional before making health decisions.